Increased mean AUC & decreased mean Cmax
w/ aspirin. Increased Cmax
, AUC & t½
w/ propranolol. Severe hypoglycemia w/ oral miconazole. Reduced mean area under prothrombin time (PT) curve & max PT values w/ coumarin anticoagulants. CYP450 2C9 inhibitors, inducers & substrates. Reduced or absence of signs of adrenergic counter-regulation to hypoglycemia w/ sympatholytic agents (β-blockers, clonidine, guanethidine & reserpine). Potentiated or reduced activity w/ acute or chronic alcohol intake. Hypoglycemic action potentiated w/ NSAIDs (eg, ibuprofen, phenylbutazone, oxyphenbutazone & azapropazone), clarithromycin, highly protein-bound drugs, coumarins, probenecid, β-blockers, salicylates, aminosalicylic acid, anabolic steroids & male sex hormones, chloramphenicol, long-acting sulfonamides, tetracyclines, quinolones, coumarin anticoagulants, fenfluramine, fibrates, ACE inhibitors, fluoxetine, MAOIs, disopyramide, allopurinol, probenecid, sulfinpyrazone, sympatholytics, cyclophosphamide, trosphosphamide, ifosfamide, miconazole, fluconazole, pentoxifylline (high dose parenteral), tritoqualine, insulin & other oral antidiabetic drugs. Hyperglycemia & loss of glycemic control w/ thiazides & other diuretics, corticosteroids, phenothiazines, chlorpromazine, thyroid products, estrogen, progestogens, nicotinic acid (high doses) & derivatives, laxatives (long-term use), OCs, phenytoin, diazoxide, glucagon, barbiturates, rifampicin, acetazolamide, adrenaline, sympathomimetics & INH.